Effect of TMS on Neuropathic Pain for Patients With Sci

NCT07293780 · tracked via the Priya Life Science Turkey tracker

Sponsor

Ankara Etlik City Hospital

Phase

Not applicable

Started

2025-12-15

Last updated

2026-02-24

Condition(s) studied

Spinal Cord InjuryNeuropathic Pain

Investigational drug(s) / intervention(s)

active TMSsham TMS

active TMS: Patients in the active or sham primary motor cortex rTMS group will receive active or sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks. Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision.

sham TMS: Patients in the active or sham primary motor cortex rTMS group will receive active or sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks. Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision.

Study summary

The aim of this study is to evaluate the efficacy of rTMS targeting the anterior cingulate cortex, another stimulation site that may be effective in the treatment of neuropathic pain, and to compare it with motor cortex stimulation.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: 1. Patients for whom at least 12 months have passed since the date of the event 2. Patients who meet the International Pain Working Group's criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months 3. Patients aged 18-65 4. Pain not attributable to other causes such as rheumatological diseases or diabetes 5. Patients with VAS \> 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, narcotics), exercise and physical therapy agents, taking into account renal function tests and other comorbidities Exclusion Criteria: 1. History of epilepsy 2. Metallic implant in the scalp 3. Cochlear implant 4. Spinal cord stimulator 5. Pacemaker 6. Presence of psychiatric illness 7. Pregnancy

Primary outcome measure(s)

visual analog scale — first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment
The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".

Trial sites (2)

Facility	City	Region	Status
Ankara Etlik City Hospital	Ankara	Yenimahalle	Recruiting
Gaziler Physical Therapy and Rehabilitation Training and Research Hospital	Ankara	Çankaya	Recruiting

More Ankara Etlik City Hospital trials in Turkey

Laparoscopic Appendectomy: Outcomes of 10 mmHg Versus 15 mmHg Intra-abdominal Pressure Starting soon

"The Effect of Adductor Canal Block Performed With Postoperative Thigh Tourniquet Application on Pain After Total Knee Arthroplasty" Enrolling by invitation

Perfusion Index for Predicting Diabetic Ketoacidosis Severity in the Emergency Department Recruiting

Effectiveness of Theta Burst Stimulation For Upper and Lower Extremity Recovery in Stroke Recruiting

45 V vs 60 V Pulsed Radiofrequency of the Cervical Dorsal Root Ganglion for Cervical Radicular Pain Recruiting

Other trials for the same condition

Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia Recruiting

Evaluation of RPNI for Symptomatic Neuromas in Lower Limb Amputees Recruiting

Virtual Reality Dual Task Training in SCI: Effects on Cognition and Cortical Activation Starting soon

High-Intensity Peripheral Magnetic Stimulation in Traumatic Peripheral Nerve Injury Recruiting

The Effect of Aromatherapy Foot Massage on Neuropathic Pain in Patients With Type2 Diabetes Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07293780 on ClinicalTrials.gov ↗ ← All trials in Turkey